Anacor Pharmaceuticals, Inc. 4
4 · Anacor Pharmaceuticals, Inc. · Filed Feb 5, 2016
Insider Transaction Report
Form 4
Zane Lee
VP, Clinical Dev & Interim CMO
Transactions
- Award
Common Stock
2016-02-03+4,375→ 44,044 total - Award
Stock Option (right to buy)
2016-02-03+22,136→ 22,136 totalExercise: $78.91Exp: 2026-02-03→ Common Stock (22,136 underlying) - Award
Performance Restricted Stock Units
2016-02-03+4,375→ 4,375 total→ Common Stock (4,375 underlying)
Footnotes (4)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2016.
- [F2]Includes shares purchased in 2016 pursuant to the Issuer's ESPP.
- [F3]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date is January 1, 2016.
- [F4]Represents performance restricted stock units granted to the Reporting Person. Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and will vest, if at all, based on the achievement of certain specified performance goals.